Guardant Health Rallies After FDA Clears Expanded Guardant360 Liquid CDx
Guardant Health shares jumped sharply in mid-day trading after the U.S. Food and Drug Administration approved Guardant360 Liquid CDx, an expanded liquid biopsy that combines genomic and epigenomic analysis, returns results in as little as seven days, and offers several-fold improved sensitivity over the prior version. The approval, which covers a g…